Today we can announce that we have finalized the Sencell Clinical DevelopmentStudy (LFC-SEN-001) and it reveals accurate sensor performance in human subjects. - This is a very important step in the right direction to develop the next generation Continuous Glucose Monitor (CGM) for people with diabetes, saysCEO Joacim Holter. In this first clinical development study, the osmotic pressure based continuousglucose sensor was clearly shown to track subcutaneous glucose concentrations atleast as good as the commercially available needle sensors. - The study output is as good as we had hoped for, and the production andproduct development has been even better than expected throughout the study.Both in an academic and strategic setup it is important for us to ensure thatour groundbreaking results are communicated clearly to the diabetes technologycommunity, and we have therefor decided to disclose our scientific results, saysHolter. The detailed results of this first-in human clinical study with Sencellwill be presented during the scientific program of the upcoming AmericanDiabetes Conference in San Diego on June 24th. - Beside successful results we are incredibly satisfied with how theorganization has overcome very challenging issues. Holter reminds that thesensor company operates with complex and pioneering sensor technology, whilealways having a focus on ensuring high quality at all stages of the process. -The Lifecare team should be very proud of what they have achieved so far, saysHolter. The clinical performance characteristics of these wired prototypes provide uswith strengthened and valuable knowledge for the next steps of productdevelopment. - We strongly believe that this forms a solid knowledge base whenwe develop the sensor with integrated wireless data transmission, says Holter. In April Lifecare announced that a sensor first used in our Clinical DevelopmentStudy had confirmed an operational longevity of 12 weeks in a continuedlaboratory (in vitro) set up. - All this together is absolutely abreakthrough, considering today's CGM technology. Hopefully this is asignificant step towards Lifecare's goal of contributing to helping people withdiabetes to live a normal life. ______________________________________________________ Lifecare AS is a clinical stage medical sensor company developing technology forsensing and monitoring of various body analytes. Lifecare's main focus is tobring the next generation of Continuous Glucose Monitoring ("CGM") systems tomarket. Lifecare enables osmotic pressure as sensing principle, combined withthe ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") onthe sensor body for read-out of pressure variations. LifecareŽs sensortechnology is referred to as "Sencell" and is suitable for identifying andmonitoring the occurrence of a wide range of analytes and molecules in the humanbody. ______________________________________________________ Contact: Joacim Holter, CEO, tel. +47 40059050, epost: joacim.holter@lifecare.attme.devThis information is considered to be inside information pursuant to the EUMarket Abuse Regulation and is subject to the disclosure requirements pursuantto Section 5-12 the Norwegian Securities Trading Act. This stock exchangeannouncement was published by Joacim Holter, CEO at Lifecare AS, on 11 Mai 2023at 10:40 CET